J&J Files 8-K on Operations & Financial Condition, Details Notes Due
Ticker: JNJ · Form: 8-K · Filed: Jan 23, 2024 · CIK: 200406
| Field | Detail |
|---|---|
| Company | Johnson & Johnson (JNJ) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: debt, financial-condition, 8-K, corporate-filing
TL;DR
**JNJ just dropped an 8-K on its financials, highlighting upcoming debt maturities.**
AI Summary
Johnson & Johnson (JNJ) filed an 8-K on January 23, 2024, to report its results of operations and financial condition. The filing specifically mentions several notes due in 2024, 2028, and 2035, including 0.650% Notes Due 2024, 5.50% Notes Due 2024, 1.150% Notes Due 2028, and 1.650% Notes Due 2035. This matters to investors because it provides an update on the company's financial health and upcoming debt obligations, which can impact future earnings and cash flow.
Why It Matters
This filing provides a snapshot of Johnson & Johnson's financial status and upcoming debt maturities, which is crucial for assessing its liquidity and future financial commitments.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information and does not indicate any immediate or significant new risks.
Analyst Insight
Investors should note the upcoming debt maturities, particularly the 2024 notes, and consider how their repayment or refinancing might impact Johnson & Johnson's cash flow and financial strategy in the near term.
Key Numbers
- 0.650% — Interest rate (for Notes Due 2024)
- 5.50% — Interest rate (for Notes Due 2024)
- 1.150% — Interest rate (for Notes Due 2028)
- 1.650% — Interest rate (for Notes Due 2035)
Key Players & Entities
- Johnson & Johnson (company) — the registrant filing the 8-K
- 0.650% Notes Due 2024 (dollar_amount) — a specific debt instrument mentioned
- 5.50% Notes Due 2024 (dollar_amount) — a specific debt instrument mentioned
- 1.150% Notes Due 2028 (dollar_amount) — a specific debt instrument mentioned
- 1.650% Notes Due 2035 (dollar_amount) — a specific debt instrument mentioned
- January 23, 2024 (date) — date of the earliest event reported
FAQ
What is the purpose of this 8-K filing by Johnson & Johnson?
The purpose of this 8-K filing is to report on the company's 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of January 23, 2024.
What specific debt instruments are mentioned in this filing?
The filing specifically mentions 0.650% Notes Due 2024, 5.50% Notes Due 2024, 1.150% Notes Due 2028, and 1.650% Notes Due 2035.
What was the 'Date of earliest event reported' for this 8-K?
The 'Date of earliest event reported' for this 8-K was January 23, 2024.
What is Johnson & Johnson's Central Index Key (CIK) according to the filing?
Johnson & Johnson's Central Index Key (CIK) is 0000200406.
What is the business address of Johnson & Johnson as stated in the filing?
The business address of Johnson & Johnson is One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-23 07:45:37
Key Financial Figures
- $1.00 — ich registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.650% Not
Filing Documents
- jnj-20240123.htm (8-K) — 34KB
- a2023q4exhibit991.htm (EX-99.1) — 64KB
- a2023q4exhibit992.htm (EX-99.2) — 1300KB
- a4q23overallresults.jpg (GRAPHIC) — 25KB
- a4q23regionalsalesresultsv2.jpg (GRAPHIC) — 29KB
- a4q23segmentsalesperforman.jpg (GRAPHIC) — 32KB
- logo.jpg (GRAPHIC) — 17KB
- 0000200406-24-000004.txt ( ) — 1786KB
- jnj-20240123.xsd (EX-101.SCH) — 3KB
- jnj-20240123_def.xml (EX-101.DEF) — 16KB
- jnj-20240123_lab.xml (EX-101.LAB) — 33KB
- jnj-20240123_pre.xml (EX-101.PRE) — 17KB
- jnj-20240123_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On January 23, 2024, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 31, 2023.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated January 23, 2024 for the period ended December 31, 2023 99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal fourth quarter and full year 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Johnson & Johnson (Registrant) Date: January 23, 2024 By: /s/ Robert J. Decker, Jr. Robert J. Decker, Jr. Controller (Principal Accounting Officer)